PharmHouse Signs Asset Purchase Agreement

·4 min read

TORONTO, March 3, 2021 /PRNewswire/ - RIV Capital Inc. ("RIV Capital" or the "Company") today announced that PharmHouse Inc. ("PharmHouse") has, as a result of its sale and investment solicitation process led by BMO Capital Markets, entered into a binding asset purchase agreement (the "Agreement") to sell various operating assets including its facility and certain equipment located at the facility. The Agreement is conditional on approval by the Ontario Superior Court of Justice in PharmHouse's proceedings under the Companies' Creditors Arrangement Act. PharmHouse is seeking to obtain such approval in the near future.

Based on the terms of the Agreement, the Company does not anticipate any material changes to the PharmHouse Recoverability Assessment presented in its condensed interim consolidated financial statements for the three and nine months ended December 31, 2020 available on the Company's profile on SEDAR at www.sedar.com.

About RIV Capital

RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.

Forward-Looking Statements

This news release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding the Company's expectation with respect to the timing of the court approval of the Agreement; the Company's estimates with regards to its liability related to the PharmHouse credit facility, and the Company's expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Our actual financial position and results of operations may differ materially from management's current expectations.

Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the possibility that the Agreement will not be completed or approved by the court; that the Company's liability with regards to the PharmHouse credit facility will materially differ from current expectations; credit, liquidity and additional financing risks for the Company and its investees; litigation risks; stock market volatility; regulatory and licensing risks; cannabis pricing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company's actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in the Company's relationship with its investees; changes in applicable laws; compliance with extensive government regulation, including the Company's interpretation of such regulation; changes in the global sentiment towards, and public opinion of, the cannabis industry; reliance on material contracts; risk of default by investees; divestiture risks; and the risk factors set out in the Company's annual information form for the year ended March 31, 2020 and the Company's management information circular, filed with the Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmhouse-signs-asset-purchase-agreement-301240030.html

SOURCE RIV Capital Inc.